Literature DB >> 22387303

Infantile neuronal ceroid lipofuscinosis: follow-up on a Spanish series.

Maria Socorro Pérez Poyato1, Montserrat Milá Recansens, Isidre Ferrer Abizanda, Rosario Domingo Jiménez, Amparo López Lafuente, Victoria Cusí Sánchez, Laia Rodriguez-Revenga, M Josep Coll Rosell, Laura Gort, Pilar Póo Argüelles, Mercé Pineda Marfa.   

Abstract

Infantile neuronal ceroid lipofuscinosis (INCL; NCL1, Haltia-Santavuori disease) is caused by mutations in the CLN1/PPT gene which are associated with an early onset INCL phenotype. The most detailed descriptions of INCL have come from Finland and a few series have been reported from southern European countries. Clinical course and follow-up of six Spanish patients with INCL are reported with the aim of assessing the chronological evolution and severity of this disease. The age at disease onset ranged from 8 to 15 months. Delayed motor skills were the initial symptom when the disease began before 12 months of age, and ataxia was the first sign when the disease began later. Cognitive decline, which is described between 12 and 18 months of age, occurred from 16 to 20 months of age. In our series early stage is characterized by motor impairment, cognitive decline and autistic features. Visual failure may appear simultaneously with the neurological symptoms, leading quickly to blindness. As reported, psychomotor regression appeared between 2 and 3 years of age. Myoclonic jerks occurred after 24 months of age and epilepsy was the last symptom of the disease. We report two novel mutations in a patient without epilepsy to date and describe the features of two siblings homozygous for the V181M (c.541G>A) mutation, associated with the most severe INCL phenotype. The clinical evolution might be helpful to identify patients affected by this rare disease. Early diagnosis is essential in order to provide genetic counselling to affected families. Our series may contribute to the study of the genotype-phenotype INCL correlation in the Mediterranean countries.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387303     DOI: 10.1016/j.gene.2012.02.013

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

Review 1.  Overview of advances in educational and social supports for young persons with NCL disorders.

Authors:  Bengt Elmerskog; Anne-Grethe Tøssebro; Rebecca Atkinson; Svein Rokne; Barbara Cole; Adam Ockelford; Heather R Adams
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-05-30       Impact factor: 5.187

2.  PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.

Authors:  Vito W Rebecca; Michael C Nicastri; Colin Fennelly; Cynthia I Chude; Julie S Barber-Rotenberg; Amruta Ronghe; Quentin McAfee; Noel P McLaughlin; Gao Zhang; Aaron R Goldman; Rani Ojha; Shengfu Piao; Estela Noguera-Ortega; Alessandra Martorella; Gretchen M Alicea; Jennifer J Lee; Lynn M Schuchter; Xiaowei Xu; Meenhard Herlyn; Ronen Marmorstein; Phyllis A Gimotty; David W Speicher; Jeffrey D Winkler; Ravi K Amaravadi
Journal:  Cancer Discov       Date:  2018-11-15       Impact factor: 39.397

3.  Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2014-11-11       Impact factor: 5.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.